Skip to content

Jazz Pharmaceuticals PLC Price, Chart & Factor Analysis

Free Data & Analytics Access

Latest earnings: November 2, 2026 results vs estimates

Jazz Pharmaceuticals PLC · E.JAZZ.NASDAQ · United States
Use symbol E.JAZZ.NASDAQ in our API & Excel add-in to retrieve this data ↓
207.83
(+0.01%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum -50%
Trend -25%
Bubble Risk LOW
Realised Volatility (20D) 28.78%

Jazz Pharmaceuticals PLC Forecast

Jazz Pharmaceuticals PLC short-term momentum is negative (up over 1 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term SELL signal. The long-term trend is negative (3 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 28.8% a year, a typical one-standard-deviation range is 199.40–216.26 over a week, 190.56–225.10 over a month and 148.01–267.65 over a year. (Signals as of 1 Nov 2026.)

Jazz Pharmaceuticals PLC Price Chart

MacroFinance.ai

Jazz Pharmaceuticals PLC Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Jazz Pharmaceuticals PLC
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Jazz Pharmaceuticals PLC
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Jazz Pharmaceuticals PLC
Signal
0
ⓘLatest reading of Signal.
Teal = supportive for Jazz Pharmaceuticals PLC, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Research on Jazz Pharmaceuticals PLC

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Jazz Pharmaceuticals PLC Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Jazz Pharmaceuticals PLC; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Jazz Pharmaceuticals PLC’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Jazz Pharmaceuticals PLC behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Jazz Pharmaceuticals PLC (United States)

Jazz Pharmaceuticals PLC is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is Jazz Pharmaceuticals PLC?
Jazz Pharmaceuticals PLC is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Jazz Pharmaceuticals PLC price?
The latest close is 207.83 (1 Nov 2026), +0.01% on the day. The price at the top of the page refreshes during the trading day.
Is Jazz Pharmaceuticals PLC in an uptrend?
As of 1 Nov 2026, short-term momentum is negative (1 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is negative (3 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Jazz Pharmaceuticals PLC?
20-day realised volatility is 28.8% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 8.3% over a month and 4.1% over a week.
What factors affect Jazz Pharmaceuticals PLC?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Jazz Pharmaceuticals PLC, grouped as Quantitative Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Jazz Pharmaceuticals PLC?
58 backtested tactical asset allocation strategies trade Jazz Pharmaceuticals PLC through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Jazz Pharmaceuticals PLC returns analysed?
The Statistical Distribution of Returns section shows the distribution of Jazz Pharmaceuticals PLC daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Jazz Pharmaceuticals PLC historical data?
In the Free historical data section of this page: the last 10 years of Jazz Pharmaceuticals PLC daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Jazz Pharmaceuticals PLC historical data (last 10 years)

Browse or instantly download the last 10 years of Jazz Pharmaceuticals PLC daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.JAZZ.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-20230.26
2026-11-19236.45
2026-11-18247.77
2026-11-17240.71
2026-11-16239.77
2026-11-13241.55
2026-11-12240.37
2026-11-11248.24
2026-11-10245.43
2026-11-09243.55
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.